Navigation Links
Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene
Date:9/27/2010

Progenika Receives CE Mark for First DNA Chip to Detect Mutations in... -- BILBAO, Spain, September 27, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, Licensing, New Products & Services Click to view news release full screen  

Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene

 

BILBAO, Spain, September 27, 2010 /PRNewswire-FirstCall/ --

- LPLchip(R) Rapidly and Precisely Detects Mutations Causing LPL Deficiency, a Cause of Acute Pancreatitis

- LPLchip(R) Identifies Patients who Could Benefit From Gene Therapy, Such as AMT's Glybera(R), Currently Under Review for EU Approval

Progenika Biopharma S.A., a pioneer in the field of personalized medicine, announced today that it has obtained the CE Mark allowing the sale in Europe of its LPLchip(R), the first DNA chip to detect mutations in the lipoprotein lipase (LPL) gene. This diagnostic tool rapidly diagnoses patients with complete and partial lipoprotein lipase deficiency (LPLD). The test has been developed under an agreement with Amsterdam Molecular Therapeutics Holding N.V. (Euronext: AMT), which has a gene therapy for patients with LPLD.

LPLD is characterised by a marked increase in triglycerides which can lead to serious complications such as acute recurring pancreatitis. Given the progressive nature of LPLD, early diagnosis is crucial to patients in order to reduce mortality and morbidity. The LPLchip(R) can precisely, quickly and economically detect more than 120 mutations in the LPL gene. The test uses Progenika's pioneering advanced DNAchip technology, which offers reliable and fast diagnosis. All that is required for analysis using the LPLchip(R) is a blood or saliva sample.

At present, there is no approved treatment for LPLD, only lifestyle moderation guidelines to minimize diets rich in fat. However, AMT has developed a new genetic treatment for LPLD, Glybera(R), which has been filed for marketing authorization with the European Medicines Agency (EMA) in early 2010. A decision on the approval is expected mid-2011.

Long term follow-up of two clinical studies conducted in Europe and Canada is ongoing, as is a third clinical study in Canada. In these three studies, Glybera(R) has shown a sizeable decrease in the incidence of pancreatitis, or acute inflammation of the pancreas, the most debilitating complication of LPLD. In addition, these studies indicate that Glybera(R) has an excellent safety profile.

About Progenika

The Progenika Group develops biochips in the field of personalised medicine aimed at the diagnosis, prognosis and prediction of response to treatment of complex illnesses in humans. The company offers molecular diagnostic tools in areas such as oncology, lipids, and nervous system disorders as well as the optimisation of their treatment.

Paramount among its technological developments are the LIPOchip(R) for the diagnosis of Familial Hypercholesterolaemia, and the BLOODchip(R) for ensuring compatibility in blood transfusions.

Founded in the year 2000, its research, development and production centres are located in the Biscay Technological Park and in Cambridge (Massachusetts, USA). It also has laboratories in the United Arab Emirates and in Kuwait. It has also set up commercial and intellectual property offices in Madrid and London.

At present, more than 150 scientists work in the company facilities and the company's products are sold in America, Europe and the Middle East.

http://www.progenika.com


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AMT Starts Development LPLChip(TM) With Progenika
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Aug. 17, 2017 Bio-Ess Laboratories, LLC Chief Science Officer, Dr. ... and present new data on Cell-Ess® Universal Titer Boost at ... Boston, MA August 21-25.  The Bioprocessing Summit convenes more than ... ... ...
(Date:8/15/2017)... announced today that its fully owned USA -operating ... City Office in Yonkers, New York to ... 2 ) homecare therapy. This new East Coast location has also ... the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New York ...
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 21, 2017 , ... The American Hospital Association (AHA) has ... Highmark Health company, to its Board of Trustees for a three-year term beginning January ... care provider organizations and individuals that are committed to the improvement of health in ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... ComplyPAK™ Compliance Management System has assisted multiple clients in successfully passing audits ... Service Organization Control Level 2 (AICPA SOC Level 2), and State Data Use ...
(Date:8/19/2017)... California (PRWEB) , ... August 18, 2017 , ... ... a partnership aimed at creating a transparent, verifiable database to help the cannabis ... distributed ledger technology, Paragon hopes to deliver a faster technology with lower fees. ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of shoes made their ... to an ambitious venture that conjoined the passions of an NBA star, a Liberty ... Liberty community. These shoes will save lives from the rampant infections transmitted through the ...
Breaking Medicine News(10 mins):